Results 91 to 100 of about 91,755 (270)

Nivolumab in the treatment of advanced renal cell carcinoma [PDF]

open access: yes, 2019
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody approved for the treatment of advanced and metastatic renal cell carcinoma. Treatment with nivolumab is characterised by favourable toxicity profile.
Tomczak, Piotr; Department of Oncology, Poznan University of Medical Sciences, Poland   +3 more
core   +1 more source

EUSICA/INSICA Position Paper on Squamous Cell Carcinoma of the Nasal Vestibule: A Distinct Clinical Entity Requiring Dedicated Classification, Treatment Strategies and Outcome Measures

open access: yesHead &Neck, EarlyView.
ABSTRACT Purpose Cancer of the nasal vestibule (CNV) differs anatomically and clinically from both sinonasal and cutaneous squamous cell carcinoma, yet lacks formal recognition as a separate clinical entity and topographical subsite; whether it is also biologically distinct has not yet been investigated.
Mischa de Ridder   +24 more
wiley   +1 more source

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

open access: yesBMC Cancer
Background In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor binimetinib ...
Elena Elez   +8 more
doaj   +1 more source

Checkpoint inhibition enhances cell contacts between CD4+ T cells and Hodgkin-Reed-Sternberg cells of classic Hodgkin lymphoma

open access: yesHaematologica
Although checkpoint molecules like CTLA-4 and PD1 have been described several years ago, checkpoint inhibitors such as Nivolumab (an anti-PD-1 antibody) have only recently been used to treat classic Hodgkin lymphoma (cHL).
Kübra Yadigaroglu   +10 more
doaj   +1 more source

Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.

open access: yes, 2018
A 71-year-old caucasian man developed a new onset cholestasis of unknown origin. His past medical history includes non-small cell lung cancer with cerebral metastasis treated by surgery, chemotherapy and nivolumab immunotherapy.
M Komuta   +11 more
core   +1 more source

Nivolumab-induced lichen planus

open access: yes, 2019
Introduction:Renal cell carcinomas account for 90% of all malignant neoplasms of the kidney. The most common types of renal cancer in adults are clear cell and papillary renal cell carcinoma; sporadic cases of renal carcinomas containing chromosomal ...
Çelik, Uğur   +5 more
core   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt   +7 more
wiley   +1 more source

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

open access: yesJournal for ImmunoTherapy of Cancer
Background Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies.
Alexandra Leary   +27 more
doaj   +1 more source

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

open access: yes, 2017
Vyshak Alva Venur,1 Monika Joshi,2 Kenneth G Nepple,3 Yousef Zakharia1 1Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Division of Hematology ...
Joshi M, Nepple KG, Zakharia Y, Venur VA
core  

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır   +32 more
wiley   +1 more source

Home - About - Disclaimer - Privacy